StimLabs launches Allacor P for acute and chronic wound care. Allacor P retains key ECM components, including collagen I and hyaluronic acid. StimLabs has announced the launch of Allacor P, a human umbilical cord device designed for acute and chronic wound management. The device received clearance from the US Food and Drug Administration (FDA) in February 2024 with the hospital solution Corplex P, which is derived from umbilical cord tissue. It claims to be the first graft derived from the human umbilical cord extracellular matrix (ECM) and is indicated for a broad spectrum of wounds. The device features a particulate format that adapts to irregular and complex wound surfaces. Allacor P retains key ECM components, including collagen I and hyaluronic acid. According to Stimlabs, this composition supports the application process across various clinical scenarios. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Last year, the product received an A Code, enabling its introduction into additional care sites. Since receiving clearance, StimLabs has focused on building scientific evidence and gathering clinical feedback from real-world use cases to support informed application of the product as it expands into new healthcare settings. StimLabs wound care clinician Dr R Daniel Davis said: "The dehydrated human umbilical cord particulate device has the potential to impact so many patients in the same way it did for a recent complex case of mine. "The dramatic improvement after just one application brought hope to my patient during a challenging time. I'm an advocate for this device; it's something providers need to try." The company's operations are currently centred on regenerative medicine with emphasis on wound care and surgical applications. In November 2025, StimLabs reported findings from a multi-centre trial of its fenestrated dehydrated complete human placental membrane (dCHPM) allograft, Relese, when used alongside standard of care for wounds that are hard to heal.

Geistlich Pharma has entered an exclusive national distribution collaboration agreement with StimLabs in the US, focusing on the commercialisation of the former's Advanced Wound Matrix, Derma-Gide.

WOLHUSEN, Switzerland-(BUSINESS WIRE)-Geistlich Pharma AG, a worldwide leader in regenerative technologies, announced an exclusive national distribution partnership agreement with StimLabs of Roswell, GA.